logo
Plus   Neg
Share
Email

Grifols To Begin Clinical Trial To Evaluate Plasma-derived COVID-19 Drug - Quick Facts

Grifols (GRFS), a global healthcare company, said it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors. The company expects the trial to begin in February 2021, with the possibility of results in the spring. About 800 patients, tested positive for the virus in a diagnostic test, will participate in the clinical study.

Grifols said the medicine, given subcutaneously, would provide immediate protection after exposure to the virus and could be used to protect the elderly and healthcare workers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chico's FAS Inc. (CHS) Tuesday reported a wider year-over-year net loss for the fourth quarter. Meanwhile, Kohl's Corp.'s (KSS) fourth-quarter net income grew 29 percent from the previous year. But Abercrombie & Fitch Co.'s (ANF) fourth-quarter net income decreased 1 percent from the prior year. The U.S. Food and Drug Administration has approved the marketing of a new robotically-assisted surgical device (RASD) that can facilitate transvaginal hysterectomy in certain patients using minimally-invasive surgical instruments. The Hominis Surgical System of Memic Innovative Surgery Ltd., the U.S. subsidiary of Israeli biotechnology company memic Ltd., has been granted marketing authorization. Canadian cannabis company Canopy Growth Corp. (CGC, WEED.TO) announced Tuesday the launch of its Cannabidiol (CBD) beverage brand Quatreau in the high-potential U.S. market. Quatreau will be sold on Canopy's one-stop U.S. e-commerce destination, www.shopcanopy.com. Quatreau is a premium ready-to-drink...
RELATED NEWS
Follow RTT